Description
Suplatast tosylate is a unique dimethylsulfonium salt marketed in Japan
for the treatment of bronchial asthma, atopic dermatitis and allergic rhinitis. Suplatast
tosylate is a potent inhibitor of IgE synthesis without suppressing IgM and IgG. The
mechanism of action for suplatast tosylate is thought to be via the inhibition of
interleukin-4 and interleukin-6 production by T-cells at the gene level. In allergic
patients, suplatast tosylate markedly improved clinical symptoms which correlated with
a significant decrease in serum IgE antibody levels.
Description
Suplatast is an antiallergic agent. It inhibits IL-4 and IL-5 production in conalbumin-stimulated D10.G4.1 murine T helper 2 (Th2) cells in a concentration-dependent manner. Suplatast (100 mg/kg) inhibits ovalbumin-induced increases in eosinophil and total cell numbers, as well as IL-4, IL-5, and IL-13, but not IFN-γ, levels in bronchoalveolar lavage fluid (BALF) in an ovalbumin-sensitized mouse model of asthma. It also inhibits ovalbumin-induced increases in ovalbumin-specific IgE in serum and bronchial hyperresponsiveness to methacholine in the ovalbumin-sensitized mouse model of asthma.
Uses
Suplatast Tosilate is a novel capsular anti-asthmatic agent that suppresses both IgE production, IL-4 and IL-5 synthesis with IC50 above 100 μM.
Uses
Suplatast Tosylate is an antiallergic drug. Suplatast Tosylate inhibits antigen-induced histamine release from mast cells as well as IgE antibody formation. Suplatast Tosylate suppresses interleukin (IL)-4 release from T cells, however in human peripheral basophils, Suplatast Tosylate inhibited the antigen-induced release of IL-13 but not IL-4.
Biological Activity
Th2 cytokine inhibitor that attenuates IL-2, IL-5 and IL-13 production and has no effect on IFN- γ production. Acts as an immunoregulator that suppresses IgE production, eosinophil infiltration and histamine release. Exhibits antiasthmatic, anti-inflammatory and antifibrotic activity in vivo and is orally active.
References
[1] Suppressive effects of anti-allergic agent suplatast tosilate (IPD-1151T) on the expression of co-stimulatory molecules on mouse splenocytes in vivo
[2] LI-WEN HSU . The effects of suplatast tosilate (IPD-1151T) on innate immunity and antigen-presenting cells[J]. Transplant immunology, 2007, 18 2: Pages 108-114. DOI:
10.1016/j.trim.2007.05.008[3] MAKOTO FURONAKA. Suplatast tosilate prevents bleomycin-induced pulmonary fibrosis in mice.[J]. Journal of Pharmacology and Experimental Therapeutics, 2009, 328 1: 55-61. DOI:
10.1124/jpet.108.141721[4] DEBAPRIYA BHATTACHARYA. Simultaneous inhibition of T helper 2 and T regulatory cell differentiation by small molecules enhances Bacillus Calmette-Guerin vaccine efficacy against tuberculosis.[J]. The Journal of Biological Chemistry, 2014, 289 48: 33404-33411. DOI:
10.1074/jbc.m114.600452[5] MARIKO WADA . Effect of Suplatast Tosilate on Antileukotriene Non-Responders with Mild-to-Moderate Persistent Asthma[J]. Allergology International, 2009, 58 3: Pages 389-393. DOI:
10.2332/allergolint.08-oa-0068
